Molecular targeted therapies for pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Pancreatic cancer exhibits mutations conferring chemo- and radio-resistance.
• Targeted therapies are effective in other solid tumors and are emerging for pancreatic cancer.
• Investigating drugs that inhibit specific pancreatic cancer mutations is crucial.

Purpose of the Study:

• To review the impact of drugs targeting specific mutations in pancreatic cancer.
• To emphasize the role of these targeted drugs in ongoing clinical trials.

Main Methods:

• Comprehensive literature review of English-language studies (MedLine).
• Inclusion of both preclinical and clinical research on targeted mutation inhibitors.
• Focus on drugs targeting specific mutations in pancreatic cancer.

Main Results:

• Preclinical studies support combining targeted therapies (EGFR, VEGF inhibitors, apoptosis inducers) with conventional treatments.
• Current clinical evidence is primarily from small Phase I trials assessing safety and toxicity.
• Ongoing randomized trials are essential for definitive results.

Conclusions:

• Targeted therapies hold potential as complementary treatments for pancreatic cancer.
• Further randomized clinical trials are necessary to establish the definitive role of these agents.
• The safety and efficacy of targeted agents in combination regimens require continued investigation.